海外の治験の状況「1」での検索結果
251件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Study for classical Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-C1
- 1st and 2nd line therapy for childhood Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications. MedDRA version: 8.1 Level: HLGT Classification code 10025319 Term: Lymphomas Hodgkin's disease
- Austria, Belgium, Denmark, France, Germany, Ireland, Netherlands, Poland, Slovenia, Spain, Sweden, United Kingdom
- 2006-09-05
Authorised
- R-CPOP (Rituximab plus Cyclophosphamid, Pixantron, Vincristin, Prednison) as first line therapy for elderly patients with diffuse-large B cell lymphoma (DLBCL) and for patients with limited cardiac function with DLBCL
- Diffuse-large B cell lymphoma (DLBCL);Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Germany
- 2014-12-30
Authorised
- A 34-week Follow-up to: A Study of Sitagliptin/Metformin in Pediatric Patients with Type 2 Diabetes Mellitus not Controlled on Metformin Therapy (Alone or in Combination with Insulin).
- Type 2 Diabetes Mellitus;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Argentina, Bulgaria, Canada, Chile, Colombia, Costa Rica, Dominican Republic, Germany, Guatemala, India, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, New Zealand, Romania, Russian Federation, Saudi Arabia, Sri Lanka, Thailand, United Arab Emirates, United Kingdom, United States
- 2014-12-22
Authorised
- The study to assess the efficacy and safety of new Interferon alpha-2b formulation in patients with primary myelofibrosis
- Primary Myelofibrosis (grade MF-0 and MF-1) according to the WHO criteria MedDRA version: 17.0 Level: LLT Classification code 10053134 Term: Osteomyelofibrosis System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Austria
- 2014-07-07
Authorised
- Comparative effectiveness of 1 month of ticagrelor plus aspirin followed by ticagrelor monotherapy versus a current-day intensive dual antiplatelet therapy in all-comers patients undergoing percutaneous coronary intervention with bivalirudin and BioMatrix family drug-eluting stent use.
- Subjects either male or female eligible for percutaneous coronary intervention (PCI) with lesions suitable for stent implantation who meet all eligibility criteria and provide written informed consent will be included. Of note, inclusion criteria will be kept comprehensive to reflect routine clinical practice (i.e. “real world, all-comers” patients). MedDRA version: 14.1 Level: PT Classification code 10011078 Term: Coronary artery disease System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Singapore, Spain, Sweden, Switzerland, United Kingdom
- 2013-03-28
Authorised
- Safety and Efficacy Study of Pegylated Interferon Lambda with and without Daclatasvir, compared to Pegylated Interferon Alfa, plus Ribavirin in Subjects with Hepatitis C Genotype 2 and 3
- Chronic Hepatitis C MedDRA version: 16.0 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, Finland, France, Greece, Hong Kong, India, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Puerto Rico, Russian Federation, Singapore, Taiwan, United Kingdom, United States
- 2012-05-28
Authorised
- A Two-Part Study of ZX008 in Children and Adults with Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults with LGS, Followed by Part 2: An Open-label Extension to Assess Long-Term Safety of ZX008 in Children and Adults with LGS
- Lennox-Gastaut Syndrome in Children and Adults MedDRA version: 20.1 Level: PT Classification code 10048816 Term: Lennox-Gastaut syndrome System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, United Kingdom, United States
- 2018-04-20
Authorised
- A Two-Part Study of ZX008 in Children and Adults with Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults with LGS, Followed by Part 2: An Open-label Extension to Assess Long-Term Safety of ZX008 in Children and Adults with LGS
- Lennox-Gastaut Syndrome in Children and Adults MedDRA version: 20.1 Level: PT Classification code 10048816 Term: Lennox-Gastaut syndrome System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, United Kingdom, United States
- 2018-03-30
Authorised
- A study to investigate the effects of the drug ARQ 087 in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholanciocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion.
- Inoperable or advanced FGFR2 gene fusion positive intrahepatic cholangiocarcinoma br>MedDRA version: 20.0 Level: LLT Classification code 10073078 Term: Intrahepatic cholangiocarcinoma recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10073077 Term: Intrahepatic cholangiocarcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States
- 2018-02-02
Authorised
- A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINK
- Overactive bladder MedDRA version: 12.0 Level: LLT Classification code 10059617 Term: Overactive bladder
- Austria, Belgium, Bulgaria, Czech Republic, France, Germany, Hungary, Italy, Spain, Sweden, United Kingdom
- 2009-08-03